Today: 9 June 2026
Hua Hong Semiconductor Class A stock: Feb 10 deal vote is the next test for 688347
25 January 2026
2 mins read

Hua Hong Semiconductor Class A stock: Feb 10 deal vote is the next test for 688347

Shanghai, Jan 25, 2026, 09:16 CST — Market closed.

  • Hua Hong Semiconductor’s Class A shares ended the session down 0.6%, closing at 139.76 yuan.
  • Investors are preparing for a February 10 vote on a share-based acquisition of Shanghai Huali Microelectronics, alongside a distinct fundraising proposal.
  • Traders are keeping an eye on pricing terms, potential dilution, and the progress of regulatory approvals.

Hua Hong Semiconductor’s Class A shares on the Shanghai exchange closed 0.6% lower Friday at 139.76 yuan, having traded in a range from 134.04 to 140.12 yuan earlier in the session.

Hua Hong’s next big step hinges on its deal calendar. According to a Hong Kong exchange circular dated Jan. 22, shareholders will vote on Feb. 10 to issue RMB shares to acquire 97.4988% of Shanghai Huali Microelectronics Corp, a 12-inch wafer foundry, for roughly 8.27 billion yuan. The payment involves issuing about 190.8 million shares at 43.34 yuan apiece. The circular also details a “non-public issuance” — akin to a private placement — aiming to raise up to 7.56 billion yuan in support funds. Pricing here is tied to a 20-day average, but won’t fall below 52 yuan, the IPO price. Innovax Capital, the Hong Kong independent financial adviser, noted: “The recent share price movement does not affect the underlying valuation.” HKEX News

The key issue now is straightforward: this is about capital and control, not just a product update. Issuing new shares brings dilution risk, and the price dynamics are crucial since Hua Hong’s A-shares have been swinging widely from day to day, making the discount calculations impossible to overlook.

A Shanghai filing detailed the process for onshore holders, setting Feb. 4 as the A-share record date. It also included a “whitewash waiver” — allowing a controlling shareholder to dodge a mandatory takeover offer if its stake rises post-issuance — plus other related-party voting restrictions. Cninfo

The Shanghai Stock Exchange’s announcements page showed Hua Hong’s notice to hold its first extraordinary general meeting of 2026, alongside a disclosure about a plan to issue A-shares to select investors. This forms the core of the private-placement move, and traders will be digging into the details when the market reopens.

The proposed acquisition also heightens the competitive landscape. Adding a 12-inch foundry operation would boost scale and capacity in specialty processes, a battleground where domestic firms are scrambling for market share as clients seek supply chain diversification.

The sector mood remains volatile. Nvidia CEO Jensen Huang was reportedly in Shanghai on Saturday, sources say, while the company awaits Beijing’s decision on whether it can sell its H200 AI chip in China. Chinese customs officials have been told the chip isn’t allowed into the country, though it’s uncertain if that constitutes an official ban.

The downside scenario is clear. The deal requires several approvals plus shareholder consent, and the fundraising hinges on market conditions and final pricing. Any delays, altered terms, or investor concerns over dilution might pressure the stock through February.

Trading picks up again Monday, with investors eyeing new filings that could narrow the timeline and clarify pricing. Any changes in chip-policy headlines will also draw attention. The key dates ahead are the Feb. 4 record date and the Feb. 10 shareholder meeting.

Stock Market Today

  • Parabilis Medicines Boosts IPO to Potential $637 Million, Set to Break Biotech Records
    June 9, 2026, 10:57 AM EDT. Cancer biotech Parabilis Medicines has raised its initial public offering target to potentially $636.8 million, aiming to surpass the record set by Kailera Therapeutics' $625 million IPO. The Massachusetts-based company plans to offer over 33 million common shares at $17 to $19 each, primarily to fund phase 3 trials of zolucatetide for desmoid tumors, a rare type of benign connective tissue growth. Parabilis leverages innovative helicon peptide drugs targeting previously undruggable pathways, notably the Wnt/b-catenin signaling linked to cancer. The firm has secured substantial private funding, including a $305 million Series F round earlier this year. If successful, Parabilis will join other biotechs such as Kailera on the Nasdaq, marking a significant entry in the biotech IPO landscape.

Latest articles

Smart Logistics Jumps 159% Before Nasdaq Halt

Smart Logistics Jumps 159% Before Nasdaq Halt

9 June 2026
Smart Logistics Global soared 158.75% to $1.33 before a Nasdaq volatility pause, putting the stock above the $1 minimum bid-price needed for compliance after months below the threshold; the company must now close at or above $1 for 10 straight business days to avoid further Nasdaq action, with no new company news driving the surge.
Reddit Shares Pop After Wall Street Sees the Right Ad Signal

Reddit Shares Pop After Wall Street Sees the Right Ad Signal

9 June 2026
Reddit shares surged 6.6% to $182.44 after Cleveland Research and Piper Sandler cited stronger ad demand and raised revenue forecasts, with Cleveland noting 45% of advertisers beat ROI targets in Q2 and Reddit taking ad share from rivals, but risks remain around user growth, AI search traffic, and high valuation.
Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
ASML stock price: What to watch before Jan. 28 earnings after Intel jolts chip mood
Previous Story

ASML stock price: What to watch before Jan. 28 earnings after Intel jolts chip mood

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday
Next Story

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday

Go toTop